Isolated diastolic hypertension in childhood increases risk of adult subclinical target organ damage

Written By :  Dr. Hiral patel
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-07-04 14:30 GMT   |   Update On 2022-07-04 14:30 GMT

China: Isolated diastolic hypertension (IDH) accounts for a higher proportion of adolescent hypertension subtypes and can increase the risk of adult subclinical target organ damage (STOD), showed a 30-year prospective cohort study results published in the Journal of Hypertension. Hypertension is one of the most important risk factors for cardiovascular disease (CVD). Hypertension...

Login or Register to read the full article

China: Isolated diastolic hypertension (IDH) accounts for a higher proportion of adolescent hypertension subtypes and can increase the risk of adult subclinical target organ damage (STOD), showed a 30-year prospective cohort study results published in the Journal of Hypertension.

Hypertension is one of the most important risk factors for cardiovascular disease (CVD). Hypertension guidelines subdivide hypertension into IDH, ISH, and mixed hypertension. Isolated diastolic hypertension (IDH) is a largely unrecognized subtype of hypertension, more commonly seen in the younger age group. IDH has usually been neglected and the treatment and awareness rates of this condition remain low. Previous studies have shown that the relationship between IDH and cardiovascular outcomes is strongly associated with age but they have focused on adults or the elderly. Data on the association of IDH in childhood with adult cardiovascular risk are scarce.

Liao, Xi'an Jiaotong University, China, and colleagues conducted a study to estimate the prevalence of IDH in adolescents and to explore the impact of IDH in childhood on adult subclinical target organ damage.

Fo the longitudinal study, researchers enrolled 1738 school children (55.4% boys) aged 6–15 years and followed them for 30 years. Their blood pressure was recorded to define the hypertension subtypes: normotension, IDH, isolated systolic hypertension (ISH), and mixed hypertension. Tracked STOD included arterial stiffness (n = 1738), albuminuria (n = 1652) and left ventricular hypertrophy (LVH) (n = 1429).

Key findings of the study,

• The prevalence of IDH, ISH and mixed hypertension was 5.4%, 2.2%, and 3%, respectively, and there was no gender difference.

• Over 30 years, 21.1% of participants developed arterial stiffness, 10.3% developed albuminuria, and 4.8% developed LVH.

• Compared with normotensive participants, IDH in childhood had a higher risk ratio (RR) of experiencing arterial stiffness (RR-1.66) and albuminuria (RR-2.27) in adults after being fully adjusted but not LVH.

• If the elevated BPin children were to be used as the reference standard, IDH in childhood was associated with adult LVH (RR-2.48).

The authors conclude that IDH accounts for a higher proportion of adolescent hypertension subtypes. The key finding was that IDH in childhood significantly increased the risk of some measures of subclinical target organ damage in adults. The cumulative long-term burden and longitudinal trends of Diastolic BP from childhood to adulthood were also associated with target organ measurements in adults.

The study results emphasize the requirement of improving the prevention, detection, and treatment of isolated diastolic hypertension in adolescents, the authors commented.

Reference:

Liao Y, Chu C, Wang Y, Zheng W, Ma Q, Hu J, Yan Y, Yang J, Yang R, Wang K, Yuan Y, Chen C, Sun Y, Mu J. Isolated diastolic hypertension in childhood and risk of adult subclinical target organ damage: a 30-year prospective cohort study. J Hypertens. 2022 Jun 22. doi: 10.1097/HJH.0000000000003183. Epub ahead of print. PMID: 35730419.

Tags:    
Article Source : Journal of Hypertension

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News